T h e use of small parenteral doses of cyanocobalamin or pteroylmonoglutamic acid in the treatment of megaloblastic anaemias has been advocated as a diagnostic as well as a therapeutic procedure (Marshall & Jandl, 1960) . The rationale of such therapeutic trials is that in megaloblastic anaemias treatment with conventional doses of either cyanocobalamin or pteroylmonoglutamic acid may result in a non-specific haematological response: that is, cyanocobalamin may induce a response when the deficiency is solely of folic acid and, conversely, pteroylmonoglutamic acid may induce a response when the deficiency is solely of cobalamins. When small doses approximating to the daily requirement are given parenterally, thus eliminating problems of absorption, non-specific responses do not occur and the response to treatment is then of diagnostic as well as therapeutic value. Previous work on therapeutic trials has been directed in the main to establishing a suitable dose of pteroylmonoglutamic acid (Marshall & Jandl, 1960; Hansen & Weinfeld, 1962) and the responses to treatment with small doses of cyanocobalamin have not been studied in detail. We have studied the responses in a group of cobalamin-deficient patients treated with I pg cyanocobalamin intramuscularly each day and report our findings in this paper.
E X P E R I M E N T A L
Sixteen patients were studied. All were anaemic and megaloblastic erythropoiesis was found on marrow biopsy. The final diagnosis in patients nos. 1-12 was Addisonian pernicious anaemia and in nos. 13 and 14 megaloblastic anaemia following partial gastrectomy. The diagnosis of intestinal malabsorption in no. 16 was based on the findings given in Table I , on evidence of malabsorption of oral glucose and on the 574 J. F. ADAMS AND OTHERS I 968 finding of mucosal atrophy on peroral jejunal biopsy. T h e diagnosis in no. 15 was not established and it was not possible to carry out further investigations.
After an observation period of 2-5 days, during which the initial diagnostic investigations were made, daily treatment with I p g cyanocobalamin given intramuscularly was begun, the first day of treatment being designated day 0. Treatment was continued for at least 14 days and the injection was given at the same time each day. During the period of treatment blood samples were obtained immediately before injection. The patients were nursed in a general ward and offered a ward diet modified to exclude liver and to contain little milk or egg. T h e daily diet was calculated to contain 70 g protein, 97 g fat, 0.6 pg cobalamins, 5 ,ug folic acids and to have an energy value of 2000 kcal. The technical methods employed were as follows: haemoglobin, packed red cell volume and reticulocyte count (Dacie & Lewis, 1963) ; augmented histamine gastric secretion (Kay, 1953) , the p H of the aspirate being measured electrometrically ; serum iron (Ramsay, 1957) ; serum folate (Waters & Mollin, 1963) ; urine xylose in the 5 h after an oral dose of 5 g (Roe & Rice, 1948) ; urine formiminoglutamic acid (Figlu) in the 4-9 h after 15 g histidine orally (Kohn, Mollin & Rosenbach, 1961) ; gastric parietal cell antibodies (Adams, Glen, Kennedy, Mackenzie, Morrow, Anderson, Gray & Middleton, 1964) ; faecal fat in a 3-day collection by the method of Cammidge (Varley, 1958) ; absorption of I ,ug radioactive cyanocobalamin by mouth (Schilling, 1953) ; in vitro intrinsic factor assay (Gottlieb, Lau, Wasserman & Herbert, 1965) and propionic acid in a 24 h collection of urine (White, 1965) . At the conclusion of each trial all samples from each patient were assayed together in at least two assays for serum vitamin B,, (Hutner, Bach & Ross, 1956) .
R E S U L T S
T h e results of the pretreatment and other diagnostic investigations are shown in Table I .
T h e pretreatment serum iron values ranged from 80 to 260 pg/Ioo ml. I n only one of twelve patients had the value fallen to 60 ,ug/Ioo ml on day 2, this value occurring in the other patients between days 3 and 15 (Table 2 ).
The reticulocyte count rose to at least 9 yo in all patients during the treatment period but the maximum value and pattern of response varied greatly. Plateau responses were more common than peak responses; when the latter did occur the maximum value occurred between days 5 and 9 (Table 3) .
Pretreatment urinary propionic acid values were high in four patients and within normal limits in two. T h e effect of treatment was observed in five of these patients, including the two with normal pretreatment values, and in one with a high value on day I : three patients showed a fall, two including one with normal pretreatment value, a rise followed by a fall, and one, with a normal pretreatment value, did not change (Table 4) .
Urinary Figlu estimations during the period of treatment were carried out in eight patients, all of whom had had an excessive amount before, or on day I or 2 of treatment. I n three the values fell and in five they were unaltered by treatment. Table I . 6.8 7' 1 7'2 7'1 7'4 6.5 Pretreatment serum vitamin B,, levels were less than 85 pg/ml in all patients.
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D I S C U S S I O N
I n clinical practice the earliest objective signs of a haematological response which follows the administration of cyanocobalarnin to an anaemic cobalamin-deficient subject are a fall in serum iron and a rise in reticulocyte count. With conventional VOl. 22 Low-dose B,, therapy in megaloblastic anaemia 579 Adams (1968) , both using whole body monitoring techniques, indicates that the requirement to maintain balance is I 968 related to the body stores of cobalamins and lies in the range O*I-O*Z yo of body stores per day. The requirement of an anaemic, cobalamin-deficient subject is thus very small and it is of interest to note that haematological responses have been induced by as little as 0.1 pg cyanocobalamin daily (Sullivan & Herbert, 1965) , the responses presumably resulting from administration of amounts greater than those required simply to maintain balance. The problem of the best dose of cyanocobalamin for therapeutic trials is difficult. In the majority of our patients the reticulocyte response was suboptimal, and as such responses may follow a variety of substances such as antibiotics, choline, serine and histidine it could be argued that a I pg dose is too small and that a larger dose, which would induce optimal reticulocyte responses, is necessary to demonstrate specificity of response. On the other hand, it is extremely unlikely that the responses in our patients were non-specific, and from this it follows that a specific response is not necessarily manifested by optimal reticulocytosis. Ungley ( I 949) considered that the reticulocyte dose response curve was sigmoid, rising gradually, then steeply and flattening out at a supramaximal level. In this instance adjustment of dosage to ensure optimal reticulocyte responses is simply a matter of clinical convenience. There is some evidence from therapeutic trials by Hansen & Weinfeld (1962) that a daily dose of 3 pg cyanocobalamin will induce optimal reticulocyte responses and, on reflection, we feel that such a dose is more suitable for clinical purposes than I pg daily.
The results of the serial urinary propionic acid and serum vitamin B,, estimations have intrinsic interest. I n cobalamin deficiency the isomerization of methylmalonyl coenzyme A to succinyl coenzyme A is reduced and the amount of methylmalonic acid in urine is increased and provides a measure of the defect (Cox & White, 1962; Vivacqua, Myerson, Prescott & Rabinowitz, 1966 ; Gompertz, Jones & Knowles, 1967) . T h e preceding reaction, carboxylation of propionyl coenzyme A to methylmalonyl coenzyme A, although not dependent on the cobalamin coenzymes, is also affected (White, 1965) and the amount of propionic acid in urine is increased. The three points of interest in the results in this series are the normal pretreatment values obtained in two patients, the rise in amount excreted during treatment in two patients and the responses to treatment in the others. T h e two normal pretreatment values may be related to the fact that the measurement is one of a metabolic consequence one stage removed from the actual defect, thus leading to a lack of precision in delineating ' normal' from ' deficient' values, a problem which is discussed by Cox, Robertson-Smith, Small & White (1968) . T h e rise in amount of propionic acid excreted by patients 2 and 5 during treatment may be explained by the demands made upon the cobalamin coenzyme stores by the reticulocyte response with the result that the methylmalonyl coenzyme A mutase is further ' stripped of' its coenzyme: this explanation is supported by the fact that the reticulocyte responses in the two patients were the greatest in the group in whom urinary propionic acid was estimated, being 20% on day 8 in no. 2 and 35 % on day 7 in no. 5 . T h e fall in urinary propionic acid in this series was slow in contrast to the rapid fall observed following treatment with conventional therapeutic doses of cyanocobalamin (Cox et al. 1968 If this is so then the degree of repletion is extremely variable and obviously minute when compared to the extent of the normal body stores. T h e very rapid rise in patients 1 3 and 14 is of interest. In both it appears that the amount of cyanocobalamin given could only just account for the difference between the value before treatment and that obtained 24 h after the first injection and sustained during the period of treatment.
These results raise the possibility that the injected cyanocobalamin released stored cobalamin into the circulation and that the observed increase was due to cobalamin en route from methylmalonyl coenzyme A isomerase in liver to bone marrow. The fact that in both patients the cobalamin deficiency followed partial gastrectomy may be relevant.
I n conclusion we comment briefly on the general clinical aspects of therapeutic trials. The diagnostic value of these procedures is obvious, particularly when microbiological assay and isotope techniques are not available. I n our experience, however, they are laborious and time consuming, fallible in cases in which the deficiency is of dietary origin unless strict dietary control is established and involve a risk to the ill patient which is not entirely negated by blood transfusion which has been found necessary by some workers. Where alternative diagnostic methods are available we consider that therapeutic trials should only be initiated after much thought, including a full appreciation of the responses which may be observed.
